Safety and immunogenicity of a seasonal quadrivalent influenza vaccine (GC3110A) in healthy participants aged > 65 years

被引：2

作者：

Kim, Tae Hyong ^{[1
]}

Choi, Jung-Hyun ^{[2
,11
,12
]}

Park, Sun Hee ^{[3
,11
]}

Yoo, Jin-Hong ^{[4
,11
]}

Lee, Dong Gun ^{[5
,11
]}

Choi, Su-Mi ^{[6
,11
]}

Kim, Yang Ree ^{[7
,11
]}

Lee, Mi Suk ^{[8
]}

Choo, Eun Ju ^{[9
]}

Choi, Hee Jung ^{[10
]}

机构：

[1] Soonchunhyang Univ, Coll Med, Dept Internal Med, Div Infect Dis,Seoul Hosp, Seoul, South Korea

[2] Catholic Univ Korea, Coll Med, Dept Internal Med, Div Infect Dis,Eunpyeong St Marys Hosp, Seoul, South Korea

[3] Catholic Univ Korea, Coll Med, Dept Internal Med, Div Infect Dis,Daejeon St Marys Hosp, Daejeon, South Korea

[4] Catholic Univ Korea, Coll Med, Dept Internal Med, Div Infect Dis,Bucheon St Marys Hosp, Bucheon, South Korea

[5] Catholic Univ Korea, Coll Med, Dept Internal Med, Div Infect Dis,Seoul St Marys Hosp, Seoul, South Korea

[6] Catholic Univ Korea, Coll Med, Dept Internal Med, Div Infect Dis,Yeouido St Marys Hosp, Seoul, South Korea

[7] Catholic Univ Korea, Coll Med, Dept Internal Med, Div Infect Dis,Uijeongbu St Marys Hosp, Uijongbu, South Korea

[8] Kyung Hee Univ, Dept Internal Med, Div Infect Dis, Sch Med, Seoul, South Korea

[9] Soonchunhyang Univ, Coll Med, Bucheon Hosp, Div Infect Dis,Dept Internal Med, Bucheon, South Korea

[10] Ewha Womans Univ, Mokdong Hosp, Dept Internal Med, Div Infect Dis, Seoul, South Korea

[11] Catholic Univ Korea, Coll Med, Dept Internal Med, Div Infect Dis, Seoul, South Korea

[12] Catholic Univ Korea, Coll Med, Incheon St Marys Hosp, Incheon, South Korea

来源：

VACCINE | 2021年 / 39卷 / 27期

关键词：

Quadrivalent Influenza Vaccine; Safety; Immunogenicity; INFECTION;

D O I：

10.1016/j.vaccine.2021.05.001

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background: Seasonal Influenza is still considered associated with seasonal morbidity and hospitalization in the elderly population. The World Health Organization (WHO) recommended seasonal quadrivalent influenza vaccine (QIV) to reduce burden of two currently circulating influenza B lineages. Until 2019 Korean National Immunization Program (NIP) recommended trivalent influenza vaccine (TIV) after ongoing debates on cost effectiveness of QIV for elderly population. Although influenza vaccine only showed modest effect on reducing influenza in elderly, this study aimed to evaluate the immunogenicity and safety of inactivated QIV in healthy participants > 65 years of age. Methods: A total of 274 healthy participants aged > 65 years received a QIV. Seroconversion-based vaccine efficacy of 4 strains of seasonal influenza was assessed 21 days after vaccination and adverse events were monitored until 180 days after vaccination. Results: The percentages of participants seroconverted after vaccination on HI antibody against each strain were 36.5% (99/271) to A/H1N1, 47.6% (129/271) to A/H3N2, 40.6% (110/271) to B Yamagata, and 49.1% (133/271) to B Victoria. The percentages of participants seroprotected after vaccination on HI antibody against each strain were 81.2% (220/271) to A/H1N1, 98.5% (267/271) to A/H3N2, 95.2% (258/271) to B Yamagata, and 93.7% (254/271) to B Victoria. There was no serious adverse event (SAE) related with the study vaccine. Conclusion: The quadrivalent split influenza vaccine is expected to offer seroprotection against influenza A and both influenza B lineages even in the elderly population. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).

引用

页码：3621 / 3625

页数：5